Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial

AIDS. 2009 Oct 23;23(16):2222-3. doi: 10.1097/QAD.0b013e32832e95f8.


To assess whether trial participants who ceased efavirenz (EFV) because of neuropsychiatric events had elevated plasma concentrations, we performed a retrospective case-control study. EFV levels were measured by high-performance liquid chromatography in stored plasma from 35 cases and 75 matched controls. All had taken EFV for at least 4 weeks. Median EFV concentrations did not differ (P = 0.77). Measurement of EFV levels in plasma collected at variable times after the last dose did not predict central nervous system intolerance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkynes
  • Anti-HIV Agents / adverse effects*
  • Anti-HIV Agents / blood
  • Benzoxazines / adverse effects*
  • Benzoxazines / blood
  • Case-Control Studies
  • Central Nervous System Diseases / chemically induced*
  • Cyclopropanes
  • Drug Administration Schedule
  • Drug Monitoring
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • Humans
  • Randomized Controlled Trials as Topic
  • Retrospective Studies
  • Risk Factors
  • Sleep Initiation and Maintenance Disorders / chemically induced*


  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • efavirenz